Insider Selling: Audentes Therapeutics, Inc. (BOLD) Major Shareholder Sells $18,984,000.00 in Stock
Audentes Therapeutics, Inc. (NASDAQ:BOLD) major shareholder Orbimed Advisors Llc sold 672,000 shares of the firm’s stock in a transaction that occurred on Friday, September 29th. The stock was sold at an average price of $28.25, for a total transaction of $18,984,000.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Orbimed Advisors Llc also recently made the following trade(s):
- On Thursday, September 7th, Orbimed Advisors Llc sold 5,000 shares of Audentes Therapeutics stock. The shares were sold at an average price of $22.35, for a total value of $111,750.00.
Shares of Audentes Therapeutics, Inc. (NASDAQ BOLD) opened at 28.01 on Monday. The stock’s market cap is $778.23 million. Audentes Therapeutics, Inc. has a 12-month low of $13.13 and a 12-month high of $33.43. The company has a 50 day moving average price of $24.77 and a 200 day moving average price of $24.77.
Audentes Therapeutics (NASDAQ:BOLD) last released its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.87) EPS for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.10). Analysts anticipate that Audentes Therapeutics, Inc. will post ($3.50) earnings per share for the current fiscal year.
BOLD has been the topic of a number of research analyst reports. Bank of America Corporation restated a “buy” rating and issued a $33.00 target price (up previously from $23.00) on shares of Audentes Therapeutics in a research report on Friday, September 22nd. ValuEngine upgraded shares of Audentes Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, August 24th. Evercore ISI initiated coverage on shares of Audentes Therapeutics in a research note on Wednesday, August 16th. They set an “outperform” rating and a $23.00 target price for the company. Finally, Zacks Investment Research cut shares of Audentes Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, August 14th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company. Audentes Therapeutics has an average rating of “Buy” and a consensus target price of $24.17.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Redmile Group LLC increased its position in Audentes Therapeutics by 77.8% during the 2nd quarter. Redmile Group LLC now owns 1,459,616 shares of the biotechnology company’s stock worth $27,922,000 after purchasing an additional 638,780 shares in the last quarter. Jennison Associates LLC raised its holdings in Audentes Therapeutics by 182.4% in the second quarter. Jennison Associates LLC now owns 846,273 shares of the biotechnology company’s stock valued at $16,189,000 after buying an additional 546,617 shares during the period. Vanguard Group Inc. raised its holdings in Audentes Therapeutics by 130.3% in the second quarter. Vanguard Group Inc. now owns 678,412 shares of the biotechnology company’s stock valued at $12,978,000 after buying an additional 383,837 shares during the period. State Street Corp raised its holdings in Audentes Therapeutics by 231.6% in the second quarter. State Street Corp now owns 221,276 shares of the biotechnology company’s stock valued at $4,234,000 after buying an additional 154,544 shares during the period. Finally, Alliancebernstein L.P. lifted its position in Audentes Therapeutics by 31.5% during the second quarter. Alliancebernstein L.P. now owns 640,654 shares of the biotechnology company’s stock valued at $12,256,000 after buying an additional 153,617 shares in the last quarter. 77.09% of the stock is owned by hedge funds and other institutional investors.
About Audentes Therapeutics
Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).
Receive News & Ratings for Audentes Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.